Maintenance of electric potential and synaptic transmission are energetically demanding tasks that neuronal metabolism must continually satisfy. Inability to fulfil these energy requirements leads to the development of neurodegenerative disorders, including Alzheimer's disease. A prominent feature of Alzheimer's disease is in fact neuronal glucose hypometabolism. Thus understanding the fine control of energetic metabolism might help to understand neurodegenerative disorders. Recent research has indicated that a novel class of signalling molecules, the inositol pyrophosphates, act as energy sensors. They are able to alter the balance between mitochondrial oxidative phosphorylation and glycolytic flux, ultimately affecting the cellular level of ATP. The neuronal inositol pyrophosphate synthesis relies on the activity of the neuron enriched inositol hexakisphosphate kinase 3 (IP6K3) enzyme. To verify an involvement of inositol pyrophosphate signalling in neurodegenerative disorders, we performed tagging single nucleotide polymorphism (SNP) analysis of the IP6K3 gene in patients with familial and sporadic late onset Alzheimer's disease (LOAD). Two SNPs in the 5′-flanking promoter region of the IP6K3 gene were found to be associated with sporadic LOAD. Characterising the functionality of the two polymorphisms by luciferase assay revealed that one of them (rs28607030) affects IP6K3 promoter activity, with the G allele showing an increased activity. As the same allele has a beneficial effect on disease risk, this may be related to upregulation of IP6K3 expression, with a consequent increase in inositol pyrophosphate synthesis. In conclusion, we provide the first evidence for a contribution of genetic variability in the IP6K3 gene to LOAD pathogenesis.
Introduction
The binding of a specific hormone/ligand (a 'first messenger') to plasma membrane receptors results in the activation of intracellular signalling cascades, mediated by small molecules that are therefore called 'second messengers'. The protein kinase A (PKA) activator cAMP and the calcium releasing factor Ins(1,4,5)P3 (hereafter IP3) represent the most classical examples of second messengers. While only two cyclic nucleotides, cAMP and cGMP, are recognized as cellular messengers, IP3 represents the forerunner of a large and growing family of signalling molecules: the inositol phosphates [1] . The lipid form, called inositides, comprises seven members that control membrane identity as well as signalling events (for review see [2] ).
The cytosolic, or water soluble, inositol phosphates encompass more than 40 identified members, able to regulate virtually every aspect of cellular physiology (for review see [3, 4] ).
Though IP3 is historically and functionally the most important inositol phosphate, recently a subfamily of these signalling molecules, the inositol pyrophosphates, generated by sequential phosphorylation of IP3 ( Figure 1A ) are gaining in interest and functional importance (for review see [5] [6] [7] ). The inositol pyrophosphates are inositol phosphate molecules containing one or more pyrophosphate (diphospho) moiety/ies. The best characterised member of this family is synthesised from the fully phosphorylated inositol phosphate IP6 (inositol hexakisphosphate, phytic acid or InsP6) and is called IP7 (diphosphoinositol pentakisphosphate or InsP7); it possesses a pyrophosphate moiety at position five ( Figure 1B ) [8] . The inositol hexakisphosphate kinase enzymes, IP6Ks, are responsible for IP7 synthesis [9] (Figure 1 A,B) .
Three IP6K genes are present in the human genome; IP6K1 (IHPK1) and IP6K2 (IHPK2, PiUS) are localised close to each other on the same cytogenetic band (3p21.31) on chromosome three, while IP6K3 (IHPK3) is localised on chromosome six (6p21.31). The PPIP5K enzymes can further phosphorylate IP7 to IP8, a species containing two pyrophosphate moieties ( Figure   1A ).
The analysis of genetically engineered yeast, amoeba and mice has associated the absence of inositol pyrophosphates with a vast array of cell biological processes. Inositol pyrophosphates regulate telomere length [10, 11] , vesicular trafficking [12] , epigenetic mechanisms [13, 14] , DNA recombination [15, 16] , ROS signalling [17] and many other activities. The ability of inositol pyrophosphates to regulate the cellular level of ATP [18] , the central molecule of intermediary metabolism, might explain the diversity of roles played by this class of molecules. These fundamental signalling roles support the notion that alteration of inositol pyrophosphate metabolism is manifested by the appearance of important human diseases such as cancer and diabetes. The generation of mouse knockout models has revealed that ip6k1 -/-mice have altered insulin signalling and are resistant to becoming obese [19] , while ip6k2 -/-mice are more susceptible to cancer [20] . Interestingly, the ip6k3 -/-mouse model displays neurological defects of motor learning and coordination [21] .
New information on inositol pyrophosphates is coming from human genetic studies where polymorphisms of IP6Ks and/or their chromosomal locus have been associated with specific traits or diseases. The IP6K1 gene is disrupted at the 3p21.31 breakpoint in a family with type 2 diabetes mellitus [22] ; interestingly, a Single Nucleotide Polymorphism (SNP) at the same genetic locus has associated IP6K1 with the pathogenesis of Crohn's disease [23] .
The IP6K2 genetic locus seems associated with variants determining human height [24] .
Remarkably, a SNP at the IP6K3 locus has also been associated with Crohn's disease in Koreans [25] . Furthermore, an IP6K3 SNP has been associated with serum phosphorus concentration [26] . This large scale genome-wide association study of serum phosphorus concentration revealed just seven gene polymorphisms associated with serum phosphorus concentration [26] , thus the association of IP6K3 with blood phosphate level is of particular relevance. This genetic study is consistent with the demonstration that inositol pyrophosphates regulate phosphate metabolism in a lower eukaryote, the yeast Saccharomices cerevisiae [27] .
While IP6K3 is biochemically the least characterised of the three mammalian IP6Ks, the characterized SNP represents the strongest genetic association published so far for any IP6Ks.
Therefore, we decided to investigate the genetic contribution of this locus to common human complex diseases, by analysing the influence of IP6K3 gene variation on the susceptibility to late onset Alzheimer's disease (LOAD), the most common form of neurodegenerative disorder in the elderly. It is characterized pathologically by neuronal loss and aggregation of two proteins, Aβ and tau, and clinically by a progressive loss of memory and impairment of cognitive ability.
Our brain has a very high ATP requirement; while this organ represents about 2% of body mass it uses 20% of oxygen consumed by a resting human [28] . Neurons have high energy requirements to maintain synaptic transmission and electric potential [29] . Several converging lines of evidence have implicated alterations in global and regional brain energetics in the pathogenesis of neurodegenerative diseases [30] . In fact, the reduction of the cerebral metabolic rate for glucose in specific brain areas is one of the striking features of Alzheimer's disease (AD) [31] . Moreover, a strong correlation between the spatial distribution of increased glycolysis, and Aβ plaques has been identified in the AD brain [32] . Therefore, since IP6K3 is expressed in neurons [21, 33] , and since inositol pyrophosphates have been shown to regulate ATP concentration by altering the glycolytic/mitochondrial metabolic ratio [18] , we hypothesized that IP6K3 variants could impact on neuronal energy homeostasis and consequently on neurodegenerative LOAD processes. In order to verify this hypothesis, we performed tagging SNP analysis of the IP6K3 gene in patients with familial and sporadic LOAD, and age-matched healthy control subjects. Two SNPs in the 5′-flanking region were found to be associated with sporadic LOAD. In vitro experiments were undertaken to examine whether these SNPs have an effect on IP6K3 promoter activity.
Material Methods

Study population
A total of 527 individuals from Southern Italy, including 280 patients with LOAD and 247 unrelated healthy controls were considered in this study. These patients were recruited at the Regional Neurogenetics Centre (Calabria, Southern Italy). According to familiarity (at least one first-degree relative with AD), the cases were classified as affected by familial LOAD (N = 138 subjects, including in the study only one case per family) or sporadic LOAD (N = 142 subjects).
Clinical diagnosis for AD was performed through the criteria of the National Institute on Aging, and the Alzheimer's Association workgroup [34] . All patients were fully characterised from a clinical point of view and a set of physical and biochemical parameters were measured. Cognitive status was investigated through Mini Mental State Examination (MMSE) [35] . MMSE scores were adjusted for age and educational level according to procedure reported in [36] .
Control subjects were recruited in the same population as AD patients in the frame of different recruitment campaigns focused on the monitoring of the quality of aging in Calabria.
All subjects were carefully assessed using a rigorous clinical history evaluation and a general/neurological examination, in order to exclude the presence of any neurological disorder. To avoid population stratification effects, only subjects with at least two generations of ancestors from the Calabria region were included in this study.
Ethics statement
The study protocol was approved by the local ethics committee and conducted in accordance with the provisions of the Helsinki Declaration; informed consent for genetic screening was obtained from the study participants or, where appropriate, a relative or legal representative. After written informed consent was signed, genomic DNA was extracted from peripheral blood, according to established protocols.
SNP Selection and Genotyping Assays
A total of 17 SNPs within approximately 30 kb encompassing the entire IP6K3 gene and its 5' and 3' flanking regions were genotyped in all subjects included in the study. The
SNPs were selected by a tagging approach using the Caucasian HapMap database (www.hapmap.org) based on pairwise r 2 (≥0.8) among common SNPs with minor allele frequency (MAF ≥0.05). The rs9469578 polymorphism, associated with serum phosphorus concentration [26] , was also included in the final tag SNP panel. Multiplex SNP genotyping was performed using iPlex Gold Genotyping Asssy and Sequenom MassArray (Sequenom, San Diego, CA, USA) technology, following the manufacturer's instructions and as previously described [37] . SNP assays were designed using Sequenom's MassARRAY Assay Design v3.0
Software. Spectra were analyzed using MassARRAY Typer v3.4 Software (Sequenom). For quality control, 5% of the total number of samples was re-genotyped to assess the reliability of the genotype identification protocols. Concordance among duplicates was greater than 99.8%
for all genotypes. For additional quality control, genotypes were excluded if Hardy-Weinberg equilibrium among controls p<0.05 or call rates <90%. Ultimately, two SNPs, rs559290 and rs6457740, were excluded from analysis because they deviated from HWE (P < 0.05), and one, r12203688, due to low genotyping success rates.
Bioinformatic analyses
To assess the potential function of the promoter phenotype-associated SNPs, in silico functional analysis was carried out using the freely available PROMO software (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) [38, 39] . The functionality of these SNPs (and those in strong linkage disequilibrium; r 2 ≥ 0.9 ) was further explored using regulatory information from the ENCODE (https://genome.ucsc.edu/ENCODE/) [40] and the Roadmap Epigenome Mapping projects HaploReg (v4.1, www.broadinstitute.org/mammals/haploreg/) [41] , and RegulomeDB (www.regulomedb.org/) [42] .
Reporter constructs
Two IP6K3 promoter regions of 777 nt containing the rs10947435 (G3392A (Pos. manufacturer's instructions. Firefly luciferase activity was normalized to Renilla luciferase activity. Differences in luciferase activity were compared using unpaired t-test.
Statistical Analysis
For each SNP, allele and genotype frequencies were estimated by gene counting from the observed genotypes. Departure from Hardy-Weinberg equilibrium was assessed for each SNP in controls using the χ2 test. Pairwise LD was estimated between SNPs based on r 2 statistics calculated in controls using Haploview software version 4.0 [43] (available from the Broad Institute at http://www.broad.mit.edu/mpg/haploview/).
Logistic regression analysis was used to examine the differences in SNP genotype frequencies between cases and controls. The association analyses were based on the estimation of the odds ratios (ORs) and their 95% confidence intervals (CIs), using sex as covariate.
Additive, dominant and recessive genetic models were evaluated for each SNP. Only the dominant model was considered where the minor allele homozygote count for either cases or controls was <5%. Akaike's Information Criterion (AIC) [44] was employed to determine the best-fitting model for each SNP.
We assessed whether there was evidence of interaction between APOE-4 and SNPs that were found significant in the case-control analyses by including both the main effects for each variant and a product term (SNP x APOE-4) in the regression models.
Statistical significance was considered to be p<0.05. As this study was exploratory, an arguably overly conservative statistical significance thresholding procedure (e.g., Bonferroni correction)
was not employed. The results were analyzed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA).
Results
Genetic Analysis
To investigate the contribution of IP6K3 genetic variability to the risk of late-onset
Alzheimer disease (LOAD), we analyzed a cohort of 280 unrelated individuals with sporadic or familial LOAD, and a similarly aged cohort of 247 cognitively normal controls.
Characteristics of the samples are given in Table 1 . Seventeen SNPs were analysed in these populations, 14 of which passed the quality check. Figure 2 shows the physical location of these SNPs, and the linkage disequilibrium (LD) pattern in the control sample. Table 2 reports the results of the logistic regression analysis and presents the best model for association with LOAD risk. The ORs, adjusted for the gender, showed that two polymorphisms, rs28607030
and rs10947435, both located in the 5′-flanking region of the gene, were associated with LOAD risk in the subgroup of patients with the sporadic form of the disease. For both SNPs the dominant model was the best-fitting model, but they were shown to have opposite effects on the disease risk. In fact, the carriers of at least one copy of the minor G allele of rs28607030
were at a decreased risk of LOAD, with a statistically significant OR of 0.57 (OR=0.57; 95% CI 0.36-0.90; p= 0.011), whereas individuals carrying at least one copy of the minor A allele of rs10947435 were at higher LOAD risk, as compared to the group of carriers (OR 1.89; 95% CI 1.15-3.12; p= 0.010).
We then tested for possible interactions between the IP6K3 SNPs and APOE status (ε4 allele) but no significant interaction was observed, indicating that IP6K3 has an independent role in LOAD, irrespective of the presence of the APOE*4 allele. Also there was no significant association for age at onset, nor for the disease severity (measured by MMSE score).
In silico functional consequences of rs28607030 and rs10947435
The identification of the two polymorphisms associated with LOAD risk in the 5′-flanking region of the IP6K3 gene suggests that they might affect IP6K3 promoter functionality. To verify this hypothesis we first subjected the IP6K3 promoter region to an in silico search for putative transcription factor binding sites. We employed the freely available PROMO software and screened the promoter using a higher stringency with a maximum matrix dissimilarity rate of 5 [38, 39] . This analysis revealed that the polymorphism rs28607030 is located at the centre of a perfectly conserved, for the G allele, c-Myc binding site CACGTG, the underline indicating the SNP polymorphism [45] . Conversely, the polymorphism rs10347435 is located at the centre of a semi-conserved CREB binding site (cAMP response element, CRE) [46] with the underlined G allele TcACGTCA in the centre and the small letter indicating a mismatch compared to the consensus palindromic CRE sequence.
Furthermore, since the observed associations might be due to different causal variants in LD with the studied ones, we annotated the two variants rs28607030 and rs10947435 and their proxies in high LD (r 2 ≥0.9) for evidence of functionality using HaploReg v4.1 and RegulomeDB databases. LD patterns showed that the rs28607030 is not in LD with any other variants, while eleven SNPs, all in IP6K3, were identified that were proxies with the rs10947435. We found promising functional implications for these SNPs (i.e. promoter and enhancer histone marks, the presence of multiple DNase I hypersensitivity sites, and transcription factor binding sites; see Supplementary Material, Table S1 for details), indicating a regulatory potential.
IP6K3 Promoter Activities
To verify the existence of any functional effects of the SNPs located in putative transcription factor binding sites in the promoter region of the IP6K3 gene, four luciferase reporter constructs containing the SNP rs10947435 and rs28607030 were generated ( Figure   3A ). Each construct was transfected into HEK293T cells and the relative promoter activities were determined by measuring luciferase expression ( Figure 3B ). This analysis revealed that while the SNP rs10947435 did not affect IP6K3 promoter fragment efficiency, the two alleles with SNP rs28607030 did show different IP6K3 promoter efficiencies. The construct pGL3K32 rs28607030, containing the G allele with a perfect match for c-Myc binding, was three times stronger that the pGL3K31 construct (the A allele). The difference in normalised luciferase activities between constructs possessing the SNP (A) or SNP (G) was statistically significant ( Figure 3B ). Similar studies were performed using human neuroblastoma SH-SY5Y cells, obtaining a substantially overlapping result ( Figure 3C ). Using SH-SY5Y we also did not observe any effect of the SNP rs10947435 while the SNP rs28607030, containing the G allele, was almost twice as strong as the construct containing the A allele.
The SNP rs10947435 is located in a semi-conserved cAMP response element (CRE), thus CREB binding may only occur after a strong stimulus. Therefore, we treated transfected HEK293T cells with forskolin, which increases the levels of cAMP by activating adenylyl cyclase. However, treating the cells with a wide range of forskolin concentration (1 to 50 M) and for 1 to 24 hours failed to reveal any effect of SNP rs10947435 on promoter activity (not shown).
Since the polymorphism rs28607030 is located at the centre of a perfectly conserved c- 
Discussion
Inositol is essential for correct neuronal development. In mouse, inositol prevents folate-resistant neural tube defects [48] . Inositol phosphate signalling is likely responsible for correct neuronal development, since neural tube defects are observable in the mouse knockout of the inositol 1,3,4-trisphosphate 5/6-kinase (ITPK1 or PPK1) [49] . Inositol phosphate signalling is not only important during development but also for fine tuning adult brain function. In fact inositol polyphosphate multikinase (IPMK) loss of activity has been associated with the pathophysiology of Huntington's disease [50] . Here, we define IP6K3 as an important player associated with LOAD. IP6K3 synthesizes the inositol pyrophosphate IP7, the best studied of a class of highly energetic signalling molecules acting as 'metabolic messengers' [51] . A recent review has in fact placed them 'between' signalling and metabolism [7] . The possible relevance of these molecules in the context of metabolic regulation is supported by several pieces of evidence. For example, inositol pyrophosphates regulate insulin secretion from pancreatic -cells [52] and insulin signalling [19] .
Metabolism and AD are intimately linked. The brain is one of the most energydemanding organs in the body. It has evolved complex metabolic networks to maintain activity and energy metabolism, and any alteration in these may contribute to the neurodegenerative process. A growing body of evidence indeed supports the notion that AD represents a brain metabolic disease. The co-existence of impaired glucose metabolism and insulin signaling in the brain has suggested that AD may represent a brain-specific form of diabetes, i.e., type 3 diabetes or an insulin-resistant brain state [53, 54] . Multiple studies have also begun to outline an intricate connection between metabolic syndrome and AD. Individuals with metabolic syndrome-associated clinical features, such as diabetes, obesity, hypertension and dyslipidemia have a higher risk of developing AD [55] [56] [57] [58] [59] .
Thus, the regulation of inositol pyrophosphate synthesis, which have a central role in cellular metabolism and are crucial for the production and use of energy, may have a key role in the correlation between metabolism and AD. Here, we provide the first evidence for a contribution of genetic variability in the IP6K3 gene, which codes for one of the enzymes responsible for inositol pyrophosphate synthesis ( Figure 1B ) in neuronal cells [21, 33] , to LOAD pathogenesis. We found that carriers of the minor allele of two IP6K3 5'-flanking region SNPs, rs28607030-G and rs10947435-A, were at decreased (OR=0.57; 95% CI 0.36-0.90; p= 0.011) and increased (OR 1.89; 95% CI 1.15-3.12; p= 0.010) risk of LOAD, respectively. The two variants were found to affect susceptibility to sporadic LOAD while they appeared to not affect the chance of familial LOAD. This finding suggests that IP6K3 is likely to confer a low risk, which is covered by the major risk factors involved in familial LOAD. In addition, unlike other risk factors, it does not modulate the effect of major risk factor such as Apolipoprotein E (APOE) [60] .
We analysed the role of the two SNPs associated with LOAD in modulating IP6K3
promoter activity by using luciferase reporter assays. The SNP rs10947435 did not mediate gene activation. This specific polymorphism is located within a semi-conserved CRE element, which is the binding site for the transcription factor CREB. However, not all putative CREs are bound by CREB in resting conditions, as CREB does not constitutively interact with chromatin and its binding depends on stimulation in neurons [61, 62] . Therefore, it is possible that our inability to observe a transcriptional readout for SNP rs10947435 is due to the technical limitations of the luciferase reporter assays. However, we favour a different explanation: the rs10947435 SNP is likely a marker for another linked functional polymorphism which may account for the observed effect on the risk of disease. According to Hapmap data, this SNP is in strong linkage disequilibrium (LD; r 2 ≥ 0.9) with 11 other SNPs within IP6K3. Moreover, in silico analysis by RegulomeDB revealed that three of the SNPs in LD with rs10947435 (Table S1 ) have the highest level of evidence for a regulatory role; therefore, we cannot exclude the possibility that one of these markers may be the actual causal variant. Further studies are required to confirm these observations.
On the contrary, analysis of SNP rs28607030 pointed to a functional role for this polymorphism, showing greater transcriptional activity of the minor rs28607030 G allele that possesses an intact c-Myc binding site, with respect to the A allele. This SNP is not in LD with other polymorphisms; therefore, it is reasonable to speculate that rs28607030 could affect the activity of the IP6K3 promoter. Therefore the beneficial effect of the rs28607030 G allele on disease risk could be related to upregulation of expression of the gene and a consequent increase in IP7 production.
We are aware of the fact that our study has some weaknesses that should be addressed.
First, a limitation of the study is the relatively small sample size, and therefore additional large studies are warranted to validate our findings. However, it is of note that all patients and controls were recruited in Calabria, a region from south Italy characterized, for historical and The arbitrary units of firefly luciferase activity were normalized to renilla luciferase activity.
Data are presented as average +/-standard deviation for experiments performed in triplicate. MMSE scores were adjusted for educational level and age at inclusion in the present study according to procedure reported in [36] . 
